Cord blood (CB) from an unrelated donor is increasingly used an alternative source of hematopoietic stem cells for adults with hematologic malignancies who lack an HLA-matched donor. However, the utilization of single-unit CB for transplantation of adult patients has been impeded by the low number of nucleated cells available from individual CB units. Direct intrabone CB injection (IBCBi) has been recently investigated as a solution to cell dose problem in adults, with the aims of minimizing non-specific loss of progenitors. We set up a phase I-II study to assess the safety and efficacy of CB transplantation by IBCBi in adult patients with advanced or high-risk hematological malignancies
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
Unrelated single unit intrabone cord blood transplantation
Azienda Ospedaliera S Croce e Carle
Cuneo, Cuneo, Italy
RECRUITINGTime to neutrophil recovery
Time frame: 28 days after transplantation
Incidence of platelet engraftment
Time frame: 100 days after transplantation
Acute graft versus host disease
Time frame: 100 days after transplantation
Chronic Graft Versus Host Disease
Time frame: One year after transplantation
Overall Survival
Time frame: One year after transplantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.